2. Search Result
Search Result
Pathways Recommended: Neuronal Signaling
Results for "

neuronal excitability

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

4

Peptides

3

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-105182
    Xanomeline
    2 Publications Verification

    LY-246708

    		 mAChR Neurological Disease
    Xanomeline, as an effective and selective muscarinic type 1 and type 4 (M1/M4) receptor agonist, increases neuronal excitability. Xanomeline can be used for the research of neurological disorders, such as schizophrenia .
    Xanomeline
  • HY-105182A
    Xanomeline tartrate
    2 Publications Verification

    LY 246708 tartrate

    		 mAChR Neurological Disease
    Xanomeline (LY 246708) is the potent agonist of muscarinic M1/M4 receptor with antipsychotic-like activity. Xanomeline (LY 246708) increases neuronal excitability. Xanomeline (LY 246708) can be used for the research of schizophrenia .
    Xanomeline tartrate
  • HY-P1626
    Acetyl tetrapeptide-15

    		Opioid Receptor Neurological Disease
    Acetyl tetrapeptide-15 is a synthetic peptide. Acetyl tetrapeptide-15 is derived from endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), a human μ-opioid agonist with selective anti-nociceptive effect. Acetyl tetrapeptide-15 reduces skin hyperreactivity producing inflammatory, chronic and neuropathic pain, by increasing the threshold of neuronal excitability in μ-opioid receptor via an endorphin-like pathway. Acetyl tetrapeptide-15 is used in the cosmetics for sensitive skin .
    Acetyl tetrapeptide-15
  • HY-170908
    Pellotine

    		5-HT Receptor Neurological Disease
    Pellotine is an alkaloid that can be isolated from Lophophora. Pellotine is the inverse agonist for 5-HT7 receptor with an EC50 of 291 nM. Pellotine exhibits good affinity to 5-HT1DR and 5-HT6R with Ki of 117 nM and 170 nM. Pellotine reduces intracellular cAMP levels, thereby reducing neuronal excitability and neurotransmitter release .
    Pellotine
  • HY-105182R
    Xanomeline (Standard)

    LY-246708 (Standard)

    		 Reference Standards mAChR Neurological Disease
    Xanomeline (Standard) is the analytical standard of Xanomeline. This product is intended for research and analytical applications. Xanomeline, as an effective and selective muscarinic type 1 and type 4 (M1/M4) receptor agonist, increases neuronal excitability. Xanomeline can be used for the research of neurological disorders, such as schizophrenia .
    Xanomeline (Standard)
  • HY-P1281
    Kaliotoxin

    		Potassium Channel Neurological Disease
    Kaliotoxin is a peptidyl inhibitor of neuronal BK-Type. Kaliotoxin can specific inhibit Kv channels and calcium-activated potassium channels. Kaliotoxin can be used for the research of the regulation of membrane potential and neuron excitability .
    Kaliotoxin
  • HY-105182AR
    Xanomeline tartrate (Standard)

    LY 246708 tartrate (Standard)

    		 Reference Standards mAChR Neurological Disease
    Xanomeline (tartrate) (Standard) is the analytical standard of Xanomeline (tartrate). This product is intended for research and analytical applications. Xanomeline (LY 246708) is the potent agonist of muscarinic M1/M4 receptor with antipsychotic-like activity. Xanomeline (LY 246708) increases neuronal excitability. Xanomeline (LY 246708) can be used for the research of schizophrenia .
    Xanomeline tartrate (Standard)
  • HY-149772
    Ciguatoxin CTX 3C

    		Others Neurological Disease Inflammation/Immunology
    Ciguatoxin CTX 3C, an immunizing and heterologous hapten, induces a rapid imbalance in neuronal excitability .
    Ciguatoxin CTX 3C
  • HY-135131
    Synthalin hydrochloride

    		iGluR Neurological Disease
    Synthalin hydrochloride is a K+ channel blocker with neuronal excitability modulating activity. Synthalin hydrochloride has an effect on NMDA-mediated depolarization, possibly through receptor-mediated modulation of L-glutamate and serotonin (5-HT). The use of Synthalin hydrochloride can enhance the understanding of changes in membrane potential of different neurons and help study the role of polyamines in neuronal excitability .
    Synthalin hydrochloride
  • HY-100842A
    (S)-3C4HPG

    		GABA Receptor Neurological Disease
    (S)-3C4HPG is a metabotropic glutamate receptor antagonist, demonstrating significant potential in modulating neuronal excitability and influencing synaptic transmission.
    (S)-3C4HPG
  • HY-N3711
    Dehydrocrenatine

    		JNK ERK Apoptosis Neurological Disease
    Dehydrocrenatidine, a β-carboline alkaloid that can be isolated from Picrasma quassioides. Dehydrocrenatidine induces cell apoptosis by activates ERK and JNK. Dehydrocrenatidine inhibits invasion and migration of cancer cells, it also suppresses neuronal excitability to exert analgesic effects .
    Dehydrocrenatine
  • HY-105182S1
    Xanomeline-d3

    LY-246708-d3

    		 Isotope-Labeled Compounds mAChR Neurological Disease
    Xanomeline-d3 (LY-246708-d3) is deuterium labeled Xanomeline. Xanomeline, as an effective and selective muscarinic type 1 and type 4 (M1/M4) receptor agonist, increases neuronal excitability. Xanomeline can be used for the research of neurological disorders, such as schizophrenia .
    Xanomeline-d3
  • HY-P2707
    α-Dendrotoxin

    α-DTX

    		 Sodium Channel Potassium Channel Others
    α-Dendrotoxin (α-DTX) is a small molecule peptide neurotoxin isolated from the venom of the African green mamba snake (Dendroaspis angusticeps). α-Dendrotoxin is also a KV1.1, KV1.2, KV1.6 and ASIC channel blocker. α-Dendrotoxin blocks potassium channels, lowers the threshold of neuronal action potentials, and increases the frequency of action potentials, thereby enhancing neuronal excitability. α-Dendrotoxin can be used in neurotoxicology research .
    α-Dendrotoxin
  • HY-148792
    Relutrigine

    PRAX-562

    		 Sodium Channel Neurological Disease
    Relutrigine (PRAX-562) is an orally active inhibitor of persistent sodium channel. Relutrigine potently and preferentially inhibits persistent INa induced by ATX-II (Nav 1.5 activator) or the SCN8A mutation N1768D with IC50 values of 141 nM and 75 nM, respectively. Relutrigine exhibits potent use-dependent block and reduces neuronal intrinsic excitability. Relutrigine has effective anticonvulsant activity .
    Relutrigine
  • HY-108578
    RuBi-4AP

    		Potassium Channel Neurological Disease
    RuBi-4AP, a derivative of 4-aminopyridine (4AP; HY-B0604), is a caged Kv channel blocker. RuBi-4AP contains a photolabile protecting group, allowing its effect to be controlled precisely in both space and time with light. RuBi-4AP can be used for the research of neuronal excitability, synaptic transmission, and signal propagation .
    RuBi-4AP
  • HY-100784
    Dihydrokainic acid

    		EAAT Neurological Disease
    Dihydrokainic acid is a glutamate transporters (especially GLT1) inhibitor. Dihydrokainic acid targets GLT1 with high affinity, effectively inhibiting its transport function. Dihydrokainic acid exerts its effect by inhibiting the uptake of glutamate, leading to an increase in extracellular glutamate concentration, thereby affecting neuronal excitability and neurotransmission. Dihydrokainic acid is mainly applied in the field of neuroscience for research on glutamate-related neural functions, epilepsy, learning, and memory .
    Dihydrokainic acid
  • HY-Y1683
    DL-Menthol

    Racementhol

    		 GABA Receptor Neurological Disease
    DL-Menthol (Racementhol) is an orally active, GABAaR positive allosteric modulator and UDP-glucuronosyltransferase (UGT) inhibitor that can cross the blood-brain barrier. DL-Menthol binds to GABAAR and exhibits an allosteric activation effect, enhancing GABA-mediated chloride influx and inhibiting neuronal excitability. DL-Menthol can induce surgical anesthesia in fish and inhibit the metabolic detoxification of tobacco carcinogens by human liver and intestinal UGT enzymes, resulting in reduced NNAL-N-Gluc production .
    DL-Menthol
  • HY-P10290
    Neuropeptide Y (human) free acid

    		Neuropeptide Y Receptor Neurological Disease
    Neuropeptide Y (human) free acid is the deamidated form of Neuropeptide Y (human, rat, mouse) (HY-P0198). The amidation of Neuropeptide Y C-terminal tyrosine is critical for its function. Non-amidated Neuropeptide Y fails to elicit G protein signaling .
    Neuropeptide Y (human) free acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: